OncoMatch/Clinical Trials/NCT06671548
Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
Is NCT06671548 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Relugolix for heavy menstrual bleeding.
Treatment: Relugolix — The goal of this clinical trial is to determine the benefit of relugolix 40 milligrams (mg) once a day compared with placebo in heavy menstrual bleeding associated with uterine fibroids. The main question\[s\] it aims to answer are: * the benefit of relugolix 40 mg once daily in women with heavy menstrual bleeding associated with uterine fibroids * the safety of relugolix 40 mg once daily in women with heavy menstrual bleeding associated with uterine fibroids
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: gonadotropin-releasing hormone (GnRH) agonist or antagonist
Previous treatment with gonadotropin-releasing hormone (GnRH) agonists or GnRH antagonists for uterine fibroids has failed
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify